Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19

7 trials 4 recruiting

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

2 Completed trials

4 Sponsors

3 Countries

Phase II

Phase I/II

Phase I

Phase I (FiH)

Phase II: 1 Phase I/II: 4 Phase I: 1 Phase I (FiH): 1

Indications tested

Precursor B-lymphoblastic lymphoma 1 B-cell lymphoma recurrent 1 Follicular lymphoma 1 Marginal zone lymphoma 1 Diffuse large B-cell lymphoma 1 Burkitt's lymphoma 1 Mantle cell lymphoma 1 Systemic lupus erythematosus 1 B-cell lymphoma refractory 1 Idiopathic inflammatory myopathy 1

Sponsors using this IMP

Miltenyi Biomedicine GmbH 3 Centre Hospitalier Universitaire De Nantes 2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 Ospedale Pediatrico Bambino Gesu 1

All trials

7 total

A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc… Pending

2024-519511-33-00 Phase II 1 country Centre Hospitalier Universitaire De Montpellier
CARLA-M19 : “Prospective non-randomized phase I/II study investigating the safety of CD19 CAR-T cells in patients with refractory/relapsed A… Recruiting

2023-509212-29-01 Phase I/II 1 country Centre Hospitalier Universitaire De Lille
Anti-CD19 CAR T-Cell TherApy in Refractory Systemic Autoimmune DISeases - CATARSIS Recruiting

2024-511293-74-01 Phase I/II 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies Recruiting

2022-501648-14-00 Phase I/II 1 country Miltenyi Biomedicine GmbH
CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE Recruiting

2024-516819-24-00 Phase I/II 1 country Miltenyi Biomedicine GmbH
CD19-CAR_Lenti in pediatric patients affected by relapsed/refractory B-ALL or aggressive B-NHL Ended

2024-519174-39-00 Phase I (FiH) 1 country Ospedale Pediatrico Bambino Gesu
MB-CART19.1 r/r CD19+ BCM Ended

2024-513334-38-00 Phase I 1 country Miltenyi Biomedicine GmbH

Showing 1–7 of 7 trials

← All drugs A–Z